All companies › CBIO

CBIO · CRESCENT BIOPHARMA, INC.

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells9
Research cases0
Last filing2026-09-18

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-09-16 — McNeill Jonathan · sold 731 @ $17.90 2026-09-16 — Brumm Joshua T · sold 1,610 @ $17.90 2026-09-16 — Bispham Barbara Harlin · sold 620 @ $17.90 2026-09-16 — Scalzo Richard William · sold 568 @ $17.90 2026-09-16 — Im Ellie Eunkyung · sold 623 @ $17.90 2026-09-16 — Pinkas Jan · sold 658 @ $17.90 2026-09-16 — Lynch Ryan · sold 240 @ $17.90 2026-09-18 — McNeill Jonathan · sold 3,839 @ $16.71 2026-09-18 — Brumm Joshua T · sold 7,837 @ $16.71
2026-09-162026-09-18

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

McNeill Jonathan President and COO
Brumm Joshua T Chief Executive Officer, Director
Bispham Barbara Harlin See Remarks
Scalzo Richard William Chief Financial Officer
Im Ellie Eunkyung Chief Medical Officer
Pinkas Jan Chief Scientific Officer
Lynch Ryan See Remarks
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $CBIO is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-09-18', 'insider_name': 'McNeill Jonathan', 'insider_title': 'President and COO', 'transaction_type': 'Open-market sell', 'shares': 3839.0, 'price': 16.71, 'value': 64149.69, 'is_buy': False}, {'transaction_date': '2026-09-18', 'insider_name': 'Brumm Joshua T', 'insider_title': 'Chief Executive Officer, Director', 'transaction_type': 'Open-market sell', 'shares': 7837.0, 'price': 16.71, 'value': 130956.27, 'is_buy': False}, {'transaction_date': '2026-09-16', 'insider_name': 'McNeill Jonathan', 'insider_title': 'President and COO', 'transaction_type': 'Open-market sell', 'shares': 731.0, 'price': 17.9, 'value': 13084.9, 'is_buy': False}, {'transaction_date': '2026-09-16', 'insider_name': 'Brumm Joshua T', 'insider_title': 'Chief Executive Officer, Director', 'transaction_type': 'Open-market sell', 'shares': 1610.0, 'price': 17.9, 'value': 28819.0, 'is_buy': False}, {'transaction_date': '2026-09-16', 'insider_name': 'Bispham Barbara Harlin', 'insider_title': 'See Remarks', 'transaction_type': 'Open-market sell', 'shares': 620.0, 'price': 17.9, 'value': 11098.0, 'is_buy': False}, {'transaction_date': '2026-09-16', 'insider_name': 'Scalzo Richard William', 'insider_title': 'Chief Financial Officer', 'transaction_type': 'Open-market sell', 'shares': 568.0, 'price': 17.9, 'value': 10167.2, 'is_buy': False}, {'transaction_date': '2026-09-16', 'insider_name': 'Im Ellie Eunkyung', 'insider_title': 'Chief Medical Officer', 'transaction_type': 'Open-market sell', 'shares': 623.0, 'price': 17.9, 'value': 11151.7, 'is_buy': False}, {'transaction_date': '2026-09-16', 'insider_name': 'Pinkas Jan', 'insider_title': 'Chief Scientific Officer', 'transaction_type': 'Open-market sell', 'shares': 658.0, 'price': 17.9, 'value': 11778.2, 'is_buy': False}, {'transaction_date': '2026-09-16', 'insider_name': 'Lynch Ryan', 'insider_title': 'See Remarks', 'transaction_type': 'Open-market sell', 'shares': 240.0, 'price': 17.9, 'value': 4296.0, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for CBIO today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.